Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000950170-23-014787
Filing Date
2023-04-26
Accepted
2023-04-26 16:06:04
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A glue_2023_naa_card.htm DEFA14A 13663
2 GRAPHIC img258586199_0.jpg GRAPHIC 2247455
3 GRAPHIC img258586199_1.jpg GRAPHIC 190068
  Complete submission text file 0000950170-23-014787.txt   3366088
Mailing Address 645 SUMMER STREET SUITE 102 BOSTON MA 02210
Business Address 645 SUMMER STREET SUITE 102 BOSTON MA 02210 617-949-2643
Monte Rosa Therapeutics, Inc. (Filer) CIK: 0001826457 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-40522 | Film No.: 23849720
SIC: 2836 Biological Products, (No Diagnostic Substances)